Therapeutic Effects of Enrofloxacin in Mastitis-metritis-agalactia Syndrome: A Review

Abstract

The efficacy of enrofloxacin in the mastitis-metritis-agalactia (MMA)-syndrome was inspected by necessary clinical trials and by using a meta-analysis or systematic review. Numerous aetiologies or pathophysiologies can be involved in the MMA-syndrome. Fever, anorexia, vulva discharge and mastitis are the basic changes but the growth rate and survival of the litter are the main problem of MMA. Our survey included 6 studies, of which four were entered in the meta-analysis itself; two studies dealt with the susceptibility profile of bacteria to enrofloxacin. As evident from the meta-analysis, enrofloxacin was effective in the treatment of the MMA-syndrome in pigs. Out of all studies, the results were statistically significant (p < 0.05) in three of them, whereas the overall result of metaanalysis indicates a high efficacy of enrofloxacin (p = 0.002) in treatment of the MMA syndrome. In total, there were not more than 0.3% of less susceptible and non-resistant strains out of all surveyed strains E. coli (n = 295) within MMA-sydrome and the MIC value for E. coli ranged between 0.03 and 0.06 μg/ml. The high efficacy of enrofloxacin in the MMA-syndrome therapy has been confirmed by meta-analysis and systematic review.